A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in greece

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 1242-1244

  Dimopoulos, George ^a,b   Velegraki, Aristea ^c   Falagas, Matthew E ^b,d,e  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CONTROLLED STUDY; EPIDEMIC; FUNGAL STRAIN; FUNGUS ISOLATION; GREECE; HEALTH SURVEY; HUMAN; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 62949089901     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01368-08     Document Type: Article

References (22)

1. Arabatzis, M., K. Kollia, P. Menounos, M. Logotheti, and A. Velegraki. 2004. Delineation of Clavispora lusitaniae clinical isolates by PCR-SSCP analysis of the 1TS1 region, a retrospective study comparing five typing methods. Med. Mycol. 42:27-34.
2. Bassetti, M., E. Righi, M. Tumbarello, A. Di Biagio, R. Rosso, and C. Viscoli 2006. Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Rev. Anti. Infect. Ther. 4:875-885.
3. Bassetti, M., E. Righi, A. Costa, R. Fasce, M. P. Molinari, R. Rosso, F. B. Pallavicini, and C. Viscoli. 2006. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect. Dis. 10:6-21.
4. Belazi, M., A. Velegraki, A. Fleva, I. Gidarakou, L. Papanaum, D. Baka, N. Daniilidou, and D. Karamitsos. 2005. Candidal overgrowth in diabetic patients: potential predisposing factors. Mycoses 48:192-196.
5. Blumberg, H. M., W. R. Jarvis, J. M. Sonde, J. E. Edwards, J. E. Patterson, M. A. Pfaller, M. S. Rangel-Frausto, M. G. Rinaldi, L. Saiman, R. T. Wiblin, and R. P. Wenzel for the National Epidemiology of Mycoses Survey (NEMIS) Study Group. 2001. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multi- center study. Clin. Infect. Dis. 33:177-186.
6. Chryssanthou, E., and M. Cuenca-Estrella. 2002. Comparison of the antifungal susceptibility testing Subcommittee of the European Committee on Antibiotic susceptibility testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J. Clin. Microbiol. 40:3841-3844.
7. Dimopoulos, G., F. Ntziora, G. Rachiotis, A. Armaganidis, and M. E. Fal-agas, 2008. Candida albicans versus non-albicans bloodstream infection in critically ill patients: differences in risk factors and outcomes. Anesth. Analg. 106:523-529.
8. Falagas, M. E., K. E. Apostolou, and V. D. Pappas, 2006. Attributable mortality of candidemia: a systematic review of matched cohort and case- control studies. Eur. J. Clin. Microbiol. Infect. Dis. 25:419-425.
9. Lass-Florl, C, A. Mayr, S. Perkhofer, G. Hinterberger, J. Hausdorfer, C. Speth, and M. Fille. 2008. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents. Chemother. 52:3637-3641.
10. Leon, C, F. Alvarez-Lerma, S. Ruiz-Santana, M. A. Leon, J. Nolla, R. Jorda, P. Saavedra, and M. Palomar for the EPCAN Study Group. 2008. Fungal colonization and/or infection in non-neutropenic critically ill patients: results of the EPCAN observational study. Eur. J. Clin. Microbiol. Infect. Dis. [Epub ahead of print.] doi:10.1007/s.l0096-008-0618-z.
11. Linton, C. J., A. M. Borman, G. Cheung, A. D. Holmes, A. Szekely, M. D. Palmer, P. D. Bridge, C. K. Campbell, and E. M. Johnson. 2007. Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United kingdom mycology reference laboratory. J. Clin. Microbiol. 45:1152-1158.
12. Lolis, N.j D. Veldekis, H. Moraitou, S. Kanavaki, A. Velegraki, C. Tri- andafyllidis, C. Tasioudis, A. Pefanis, and I. Pneumatikos. 2008. Saccharo- rnyces houlardii fungaemia in an intensive care unit patient treated with caspofungin. Crit. Care 12:414.
13. Magill, S. S.j S. M. Swoboda, E. A. Johnson, W. G. Merz, R. K. Pelz, P. A. Lipsett, and C. W. Hendrix. 2006. The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients. Diagn. Microbiol. Infect. Dis. 55:293-301.
14. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2.000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
15. Pai, M. P., A. L. Jones, and C. K. Mullen. 2007. Micafungin activity againstCandida bloodstream isolates: effect of growth medium and susceptibility testing method. Diagn. Microbiol. Infect. Dis. 58:129-132.
16. Peres-Bota, D-, H. Rodriguez-Villalobos, G. Dimopoulos, C. Melot, and J. L. Vincent. 2004. Infections with Candida spp. in critically ill patients are primarily related to the length of stay in the intensive care unit. Clin. Microbiol. Infect. 10:550-555.
17. Pfaller, M. A., D. J. Diekema, R. N. Jones, H. S. Sader, A. C. Fluit, R. J. Hollis, and S. A. Messer for the SENTRY Participant Group. 2001. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravucon- azole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 39:3254- 3259.
18. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. J. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. Antimicrob. Agents Chemother. 46:2620-2629.
19. Richards, M. J., J. R. Edwards, D. H. Culver, and R. P. Gaynes. 2000. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect. Control Hosp. Epidemiol. 21:510-515.
20. Rodriguez-Tudela, J. L., J. P. Donnelly, M. A. Pfaller, E. Chryssantou, P. Warn, D. W. Denning, A. Espinel-Ingroff, F. Barchiesi, and M. Cuenca- Estrella. 2007. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J. Clin. Microbiol. 45:109-111.
21. Schelenz, S. 2008. Management of candidiasis in the intensive care unit. J. Antimicrob. Chemother. 61(Suppl. I):i31-i34.
22. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.